🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "major milestone" in the fight against superbug strains of the bacteria, according to scientists.

A Worldwide Challenge

The sexually transmitted infection are escalating globally, with estimates suggesting in excess of 82 million instances annually. Notably increased rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune step in the face of increasing worldwide cases, escalating drug resistance and the highly restricted available drugs presently on offer.”

Health officials are increasingly worried about the surge in treatment-resistant strains. The global health body has classified it as a "high-priority threat". A tracking program showed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Receive Approval

Zoliflodacin, alternatively called a brand name, was approved by the US FDA in recent days for combating gonorrhoea. This infection can lead to significant complications, including infertility. Experts anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This medication, which is also used to treat UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a unique collaborative effort for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This authorization marks a major breakthrough in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Data and Global Access

According to findings released by a prominent scientific publication, zoliflodacin cured more than 90% of cases of the STI. This puts it on an equal footing with the typical regimen, which uses a dual-drug approach. The trial included over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the rights to license and sell the drug in many low-income and middle-income countries.

Clinicians on the front lines have shared positive views. The availability of a single-dose, oral treatment like this is seen as a "game-changer" for managing the epidemic. This is deemed essential to alleviate the strain of the illness for people and to stop the proliferation of untreatable gonorrhoea globally.